Aytu Biopharma Inc
AYTU
查看详细走势图
2.550USD
+0.080+3.24%
收盘 12/19, 16:00（美东）报价延迟15分钟
25.28M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.24%
5天
+10.87%
1月
+31.44%
6月
+27.50%
今年开始到现在
+50.00%
1年
+84.78%
查看详细走势图
TradingKey Aytu Biopharma Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Aytu Biopharma Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名77/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.17。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Aytu Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
9.167
目标均价
+309.23%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Aytu Biopharma Inc亮点
亮点风险
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
业绩增长期
公司处于发展阶段，最新年度总收入66.38M美元
估值低估
公司最新PE估值-1.16，处于3年历史低位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值95.12K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.49
Aytu Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Aytu Biopharma Inc简介
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
公司代码AYTU
公司Aytu Biopharma Inc
CEODisbrow (Joshua R)
网址https://aytubio.com/
常见问题
Aytu Biopharma Inc(AYTU)的当前股价是多少？
Aytu Biopharma Inc(AYTU)的当前股价是 2.550。
Aytu Biopharma Inc的股票代码是什么？
Aytu Biopharma Inc的股票代码是AYTU。
Aytu Biopharma Inc股票的52周最高点是多少？
Aytu Biopharma Inc股票的52周最高点是2.820。
Aytu Biopharma Inc股票的52周最低点是多少？
Aytu Biopharma Inc股票的52周最低点是0.950。
Aytu Biopharma Inc的市值是多少？
Aytu Biopharma Inc的市值是25.28M。
Aytu Biopharma Inc的净利润是多少？
Aytu Biopharma Inc的净利润为-13.56M。
现在Aytu Biopharma Inc(AYTU)的股票是买入、持有还是卖出？
根据分析师评级，Aytu Biopharma Inc(AYTU)的总体评级为买入，目标价格为9.167。
Aytu Biopharma Inc(AYTU)股票的每股收益（EPS TTM）是多少
Aytu Biopharma Inc(AYTU)股票的每股收益（EPS TTM）是-2.194。
相关品种
